Evolution of the Average Target: Amrize AG

Evolution of the Target Price: Amrize AG

Changes in Analyst Recommendations: Amrize AG

8c9.onP3kys61YjrOSYHV4gjBX_-T1O6_0LrkZxxxKOl5Gs.5Cy4o3kPs9eGTh51Ibhwdy2_LAHcphCn869Jie7nqSf0PJ75T2rs5NNrdw~5d34d27a88c623b2f3bb53c9af1d4c19
01:59pm Morgan Stanley Cuts Amrize's PT, Affirms Overweight Rating MT
08-18 Berenberg Cuts Amrize Price Target After 'Slightly Disappointing' Q2; Buy Retained MT
08-10 Amrize's Q2 Earnings Miss, EBITDA Guidance Cut Raise Execution Concerns, RBC Capital Markets Says MT
08-10 Oddo BHF Cuts Amrize PT, Keeps Neutral Rating MT
08-10 RBC Downgrades Amrize to Underperform From Sector Perform, Adjusts PT to $48 From $60 MT
07-21 Oppenheimer Adjusts Price Target on Amrize to $65 From $68, Maintains Outperform Rating MT
07-07 Truist Downgrades Amrize to Hold From Buy, Cuts Price Target to $48 From $65 MT
05-14 Morningstar Upgrades Amrize's Rating to Buy MT
05-01 Oppenheimer Adjusts Price Target on Amrize to $68 From $70, Maintains Outperform Rating MT
05-01 RBC Trims Price Target on Amrize to $60 From $61, Keeps Sector Perform Rating MT
02-26 On Field Investment Research Downgrades to Neutral Rating, Raises PT MT
02-23 Deutsche Bank Adjusts Amrize Price Target to $70 From $59, Maintains Buy Rating MT
02-20 Truist Raises Price Target on Amrize to $75 From $60, Keeps Buy Rating MT
02-19 RBC Capital Adjusts Price Target on Amrize to $61 From $60, Maintains Sector Perform Rating MT
02-19 Berenberg Adjusts Price Target on Amrize to $70 From $64, Maintains Buy Rating MT
02-19 Oppenheimer Adjusts Price Target on Amrize to $70 From $64, Maintains Outperform Rating MT
01-08 UBS Adjusts Price Target on Amrize to $57 From $53, Maintains Neutral Rating MT
12-08 Amrize Shares Fall After RBC Downgrade MT
12-08 RBC Downgrades Amrize to Sector Perform From Outperform, Lifts Price Target to $60 From $56 MT
11-26 Vertical Research Starts Amrize Coverage with Hold Rating MT
11-04 Oddo BHF Kicks Off Amrize Coverage with Neutral Rating MT
11-03 UBS Adjusts Price Target on Amrize to $53 From $52, Maintains Neutral Rating MT
29/10/25 Swiss stocks - Factors to watch on October 29 RE
28/10/25 On Field Investment Research Upgrades Amrize to Outperform, Raises PT MT
24/10/25 JPMorgan Kicks Off Amrize Coverage with Overweight Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+48.4%
+19.84%
+21.05%
+38.07%
+26.75%
+40.39%
+33.17%
+39.15%
Average +33.35%
Weighted average by Cap. +34.26%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
44.46USD
Average target price
58.52USD
Spread / Average Target
+31.61%
High Price Target
71.70USD
Spread / Highest target
+61.27%
Low Price Target
49.39USD
Spread / Lowest Target
+11.08%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

ODDO BHF
RBC Capital Markets
Oppenheimer
Truist Securities
Morningstar
On Field Investment Research
Deutsche Bank Securities
Berenberg Bank
UBS
Vertical Research
JPMorgan
Kepler Cheuvreux
Wells Fargo Securities
Barclays
Bernstein
BNP Paribas
Deutsche Bank Research
CIC Market Solutions
Morgan Stanley
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
44.46USD
Average target price
58.52USD
Spread / Average Target
+31.61%

Quarterly revenue - Rate of surprise